Aubagne

Researchers are comparing two methods for the second reading of screening mammograms in women aged 50 to 74 as part of a breast cancer screening program. The study aims to determine if the AI-assisted reading process is not worse than the standard radiologist reading and if it may be more cost-effective. It focuses on mammograms deemed normal or showing benign lesions from the first reading. Participants mammograms undergo two review paths the standard second reading by a certified radiologist, and an AI-assisted reading where mammograms flagged as suspicious by the AI are then reviewed by a radiologist. The final decision is based on the more concerning assessment from either method. Women will be recalled for further exams if either reading indicates suspicion. During the study, participants receive screening mammograms and their results are monitored for recall rate, cancer detection, sensitivity, specificity, economic impact, time to results, and reading time. The study will follow up for up to 48 months to measure these outcomes. Participants must consent and meet eligibility requirements related to health, imaging quality, and availability for the study duration.

This research aims to study people who have had their first episode of symptomatic deep vein thrombosis DVT in their lower limbs to understand the risk and severity of post-thrombotic syndrome PTS, the most common long-term complication of DVT. The study focuses on evaluating how the amount of thrombosis blood clot burden measured by the Venous Volumetric Index VVI on ultrasound relates to the development and severity of PTS assessed by the Villalta scale over 6 months. Participants will be followed at multiple times around 1 week, 1 month, 3 months, and 6 months after diagnosis. At each visit, doctors will assess symptoms and signs to calculate the Villalta score and perform venous ultrasounds to measure thrombosis burden using the VVI. Blood samples will be collected at several visits to study inflammation, coagulation, and clot breakdown factors. Quality of life questionnaires will also be completed at 3 and 6 months. During the study, symptom assessments, ultrasound exams, blood tests, and questionnaires will help researchers understand how the thrombosis burden at baseline and over time relates to the occurrence and severity of PTS. The study ends with the 6-month visit. Researchers will monitor the presence of moderate to severe PTS and changes in clot burden to identify important prognostic factors that may guide future prevention and treatment strategies.

This research aims to understand how Hizentra, a subcutaneous immunoglobulin treatment, is used in the care of adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a rare autoimmune neurological disorder. The study focuses on the process and effects of switching patients from intravenous immunoglobulin IVIg to subcutaneous immunoglobulin SCIg therapy, exploring real-life conditions, tolerability, and treatment effectiveness using patient-reported outcomes. This observational study is sponsored by CSL Behring and is conducted across multiple centers nationally. Participants will be monitored over a 36-month period, including a 24-month enrollment phase and a 12-month follow-up. Treatment involves switching from IVIg to Hizentra, a subcutaneous injection solution, with no active intervention by researchers. The study tracks the timing, dosage, administration frequency, and methods of Hizentra use in everyday practice, including self-administration or assistance by a nurse. During the study, participants will use a patient application to report outcomes related to treatment tolerance and efficacy. Researchers will collect data on disability scales, walking tests, quality of life scores, and medication dosing details at regular intervals throughout the 12-month follow-up. The main outcome measured is the length of time participants continue treatment with Hizentra. Safety and treatment effects will be monitored without altering participants usual care.

Hospitalization in intensive care can be very traumatic and may lead to long recovery times affected by anxiety, depression, or post-traumatic stress disorder PTSD, collectively known as post-intensive care syndrome PICS. These conditions can last for years and impact patients quality of life, increasing the need for psychotropic medications and mental health services. This research aims to reduce the traumatic experience of intensive care stays by improving conditions and practices of healthcare professionals in intensive care units. It builds on previous studies, including IPREA3, by using updated assessment tools and longer program implementation. The study evaluates a tailor-made, multi-component program called PREMREA, led by a doctor and a non-medical caregiver duo. This program includes patients completing an 18-item discomfort questionnaire IPREA on the day they leave intensive care, monthly feedback sessions for staff about patient discomfort scores, and the introduction of specific care measures to improve patient experience. The program allows a longer learning period of nine months to help healthcare teams adopt new humanizing care practices, supported by conferences led by patient experts. Participants will be patients discharged alive from intensive care after a stay of at least three days. They will complete the discomfort questionnaire themselves to report their experience. Researchers will measure the overall discomfort score three months after intensive care discharge as the primary outcome. The study involves monitoring the implementation of care improvements and providing monthly feedback to staff. Participation includes signing informed consent and speaking French. The study will run until the end of 2027, aiming to assess how these interventions affect patient discomfort and recovery.

Researchers are studying the use of ziconotide, a drug delivered directly into the spinal fluid, for managing chronic non-cancer pain that does not respond to standard treatments. While ziconotide is commonly used in cancer patients, its use for other types of long-lasting pain is less documented. This study aims to collect detailed information on patients with various non-cancer pain conditions, such as spinal cord injury, neuropathies, and fibromyalgia, who are treated with intrathecal ziconotide to better understand its role in this population. The study follows patients who receive ziconotide through an implanted pump that delivers the medication into the spinal fluid. Patients may be enrolled either retrospectively or prospectively and will be observed for up to two years after starting treatment. This includes those new to intrathecal therapy, as well as those already receiving treatment without ziconotide but scheduled to add it. Data will be collected on how ziconotide therapy is started, adjusted, and managed throughout the study period. Participants will be monitored through assessments capturing their medical history, pain characteristics, neuro-psychiatric status, disability, anxiety, and depression levels at treatment start and during follow-up. The study will also track changes in pain intensity, treatment safety, and overall care over two years. The researchers aim to describe the patients profiles and how their pain and related conditions evolve while receiving ziconotide-based intrathecal analgesia.